NavidHafezMD
Oncology • Los Angeles, CABreast Cancer, Thoracic Cancer, Clinical Pharmacology
Physician
Dr. Hafez is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
11800 Wilshire Blvd
Los Angeles, CA 90025Phone+1 310-231-2121Fax+1 203-688-4516
Summary
- Dr. Navid Hafez is an oncologist in Los Angeles, CA and is affiliated with The Angeles Clinic and Research Institute and Cedars-Sinai. He received his medical degree from University of Wisconsin School of Medicine and Public Health and completed his internal medicine residency and hematology/oncology fellowship at Yale University. He specializes in breast cancer, thoracic cancer, and early drug development and is experienced in phase 1 clinical research. He has more than 10 publications and over 500 citings.
Education & Training
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2013 - 2016- Yale-New Haven Medical CenterResidency, Internal Medicine, 2010 - 2013
University of Wisconsin School of Medicine & Public HealthClass of 2010
Certifications & Licensure
CA State Medical License 2023 - 2025
CT State Medical License 2016 - 2023- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) Start of enrollment: 2019 Jun 11
- A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Start of enrollment: 2019 Dec 12
Roles: Principal Investigator
Publications & Presentations
PubMed
- 1 citationsA Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors.Gerald Falchook, Amita Patnaik, Debra L Richardson, R Donald Harvey, Manish R Sharma
Clinical Therapeutics. 2024-03-01 - 1 citationsEfficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series.Noboru Yamamoto, Anthony Tolcher, Navid Hafez, Iwona Lugowska, Rodryg Ramlau
Oncotargets and Therapy. 2024-01-01 - 58 citationsAdagrasib in Advanced Solid Tumors Harboring aMutation.Tanios S Bekaii-Saab, Rona Yaeger, Alexander I Spira, Meredith S Pelster, Joshua K Sabari
Journal of Clinical Oncology. 2023-09-01
Press Mentions
Lung Cancer: Reasons for OptimismNovember 4th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
